Daily therapy with the oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, cuts menstrual bleeding by at least half in most women with uterine fibroids, researchers say.

Results from the LIBERTY 2 trial, involving 382 women treated at 99 sites around the world, closely mirror those from the similar-sized LIBERTY 1 trial, first reported nearly two years ago.

Relugolix (Orgovyx, Myovant Sciences) was approved by the US FDA in 2020 as a treatment for advanced prostate cancer and is now being reviewed by the regulator as a uterine fibroid therapy.

The LIBERTY studies included women aged between18 and 50. For 24 weeks, one third received placebo and another third took relugolix in combination with 1mg of oestradiol and 0.5mg of norethindrone acetate to mute relugolix side effects.